Rifamycin SV sodium in situ gelling solution matching placebo (80 mL) for rectal administration, Rifamycin 1% in situ gelling solution (80 mL) for rectal administration
CB-01-35/01
Phase 2 small_molecule active
Quick answer
Rifamycin SV sodium in situ gelling solution matching placebo (80 mL) for rectal administration, Rifamycin 1% in situ gelling solution (80 mL) for rectal administration for patients with mild to moderate left-sided ulcerative colitis is a Phase 2 program (small_molecule) at Cosmo Technologies Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cosmo Technologies Ltd
- Indication
- patients with mild to moderate left-sided ulcerative colitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active